We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BellBrook Labs Awarded Patent on Transcreener® HTS Assay for Glycosyltransferases
News

BellBrook Labs Awarded Patent on Transcreener® HTS Assay for Glycosyltransferases

BellBrook Labs Awarded Patent on Transcreener® HTS Assay for Glycosyltransferases
News

BellBrook Labs Awarded Patent on Transcreener® HTS Assay for Glycosyltransferases

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BellBrook Labs Awarded Patent on Transcreener® HTS Assay for Glycosyltransferases"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

It was announced today that the U.S. Patent and Trademark Office has awarded BellBrook Labs' Transcreener® technology its fourth patent (U.S. 7,847,066) for their innovative Glycosyltransferase assay. There are over 200 glycosyltransferases encoded in the human genome that use either UDP-, GDP- or CMP-activated sugars as the donor substrates. UDP-glycosyltransferases are the most abundant and they play a key role in metabolism of drugs.

In the Transcreener® UDP Assay, the detection of UDP produced in the enzyme reaction allows for a universal system to measure UDP-glycosyltransferase activity with any acceptor substrate. Because it allows homogenous, mix-and-read detection, the Transcreener® HTS Assay platform offers significant advantages over other assay methods that require separation steps. In combination with existing Transcreener® assays for GDP and CMP, the newly patented technology will accelerate the discovery of improved drugs targeting glycosylation events in diseases, such as cancer, type II diabetes and neurodegeneration.

Advertisement